I just don't think the economics will work for them to go forward. The competition for biosimilar's will be intense and Momenta and Baxter combined will be out of their league.
Certainly agree, in general, that FoB competition will be intense. But, keep in mind that MNTA/BAX seem to be one of the few FoB players intent on going after the fully-interchangeable market. I think that's an important point and it would seem to follow to me that, if they are successful, the economics could be quite lucrative.
I think Momenta will eventually get MC, but I'm not sure it'll be before 2014. Once they get it, I wouldn't rule out Mylan also arriving.
Just keep in mind that the economics due MNTA on mC are much better than on mL as multiple generic Copaxone entrants will not have the significant impact as we have seen with respect to generic Lovenox.
They will be profitable with MC, but as always the only value an bio can derive is from it's future and that's where Momenta fails.
Market Data 
Markets 
AI
